Amgen close to buying Onyx for $125 per share

(Reuters) – Amgen Inc is close to buying Onyx Pharmaceuticals Inc for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.